0000000001246348

AUTHOR

A. Quattrone

showing 14 related works from this author

Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability.

2007

Abstract Background Fatigue is a major problem in multiple sclerosis (MS), and its association with MRI features is debated. Objective To study the correlation between fatigue and lesion load, white matter (WM), and grey matter (GM), in MS patients independent of disability. Methods We studied 222 relapsing remitting MS patients with low disability (scores ≤ 2 at the Kurtzke Expanded Disability Status Scale). Lesion load, WM and GM were measured by fully automated, operator-independent, multi-parametric segmentation method. T1 and T2 lesion volume were also measured by a semi-automated method. Fatigue was assessed by the Fatigue Severity Scale (FSS), and patients divided in high-fatigue (FS…

AdultMalemedicine.medical_specialtyMultiple SclerosisStatistics as TopicGrey matterLesionWhite matterCentral nervous system diseaseDisability EvaluationAtrophyInternal medicinemedicineImage Processing Computer-AssistedHumansRisk factorFatigueAnalysis of VarianceBrain Mappingbusiness.industryMultiple sclerosisBrainmedicine.diseaseMagnetic Resonance ImagingSurgeryOxygenMultiple Sclerosis fatiguemedicine.anatomical_structureNeurologymultiple sclerosiFemaleNeurology (clinical)Analysis of variancemedicine.symptomAtrophybusinessbrain atrophyMRI
researchProduct

Brain atrophy and lesion load in a large population of patients with multiple sclerosis

2005

Objective: To measure white matter (WM) and gray matter (GM) atrophy and lesion load in a large population of patients with multiple sclerosis (MS) using a fully automated, operator-independent, multiparametric segmentation method. Methods: The study population consisted of 597 patients with MS and 104 control subjects. The MRI parameters were abnormal WM fraction (AWM-f), global WM-f (gWM-f), and GM fraction (GM-f). Results: Significant differences between patients with MS and control subjects included higher AWM-f and reduced gWM-f and GM-f. MRI data showed significant differences between patients with relapsing-remitting and secondary progressive forms of MS. Significant correlations bet…

AdultMalePathologymedicine.medical_specialtyAdolescentBrain mappingNerve Fibers MyelinatedCentral nervous system diseaseWhite matterMultiple sclerosisAtrophySex FactorsPredictive Value of TestsNeural PathwaysmedicineHumansAge of OnsetMultiple Sclerosis/physiopathologyAgedCross-Sectional StudieBrain MappingExpanded Disability Status Scalemedicine.diagnostic_testBrain/physiopathologybusiness.industryMultiple sclerosisBrainMagnetic resonance imagingInterferon-betaMiddle Agedmedicine.diseasePrognosislesion loadMagnetic Resonance ImagingMultiple Sclerosis/diagnosimedicine.anatomical_structureCross-Sectional Studiesmultiple sclerosiLinear ModelsDisease ProgressionEducational StatusFemaleNeurology (clinical)Age of onsetAtrophybusinessMultiple Sclerosis/complicationbrain atrophyMRI
researchProduct

Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study.

2005

Knowledge about the balance between heritable and nonheritable risk in multiple sclerosis (MS) is based on twin studies in high-prevalence areas. In a study that avoided ascertainment limitations and directly compared continental Italy (medium-prevalence) and Sardinia (high-prevalence), we ascertained 216 pairs from 34,549 patients. This gives a twinning rate of 0.62% among MS patients, significantly less than that of the general population. In continental Italy, probandwise concordance was 14.5% (95% confidence interval, 5.1-23.8) for monozygotic and 4.0% (95% confidence interval, 0.8-7.1) for dizygotic twins. Results in Sardinia resemble those in northern populations but in limited number…

MaleQuestionnairesMultiple SclerosisConcordancePopulationTwinsDizygotic twinsDisease causeMultiple Sclerosis Epidemiology TwinsCohort StudiesCohort Studies Disease Susceptibility Female Genetic Predisposition to Disease Humans Italy; epidemiology Male Multiple Sclerosis; epidemiology/genetics Questionnaires Regression Analysis TwinsSurveys and QuestionnairesmedicineHumansGenetic Predisposition to Diseaseeducationeducation.field_of_studyepidemiology/geneticsbusiness.industryMultiple sclerosismedicine.diseasePenetranceTwin studyConfidence intervalNeurologyItalyRegression AnalysisSettore MED/26 - NeurologiaFemaleepidemiologyNeurology (clinical)Disease SusceptibilitybusinessDemography
researchProduct

Frequency and clinical features of progranulin mutation carriers in a series of patients affected by frontotemporal lobar de generation: report of a …

2010

Settore MED/26 - Neurologiaprogranulin mutation frontotemporal dementia
researchProduct

Identification of a novel omozigosi mutation in the sil 1 gene in Marinesco Siogrene Syndrome.

2008

x
researchProduct

TREATMENT OF MULTIPLE SCLEROSIS WITH INTERFERON BETA IN CLINICAL PRACTICE: 2-YEAR FOLLOW-UP DATA FROM THE SOUTH ITALY MOBILE MRI PROJECT

2006

researchProduct

Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.

2006

This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up per…

medicine.medical_specialtyNeurologyMultiple SclerosisDermatologySeverity of Illness IndexInterferon beta • Multiple sclerosis • Phase IV • Odds ratioInternal medicineSeverity of illnessmedicineConfidence IntervalsHumansImmunologic FactorsMultiple sclerosiNeuroradiologyAnalysis of Variancemedicine.diagnostic_testbusiness.industryMultiple sclerosisMagnetic resonance imagingGeneral MedicineOdds ratioInterferon-betaOdds ratiomedicine.diseaseInterferon betaMagnetic Resonance ImagingConfidence intervalPsychiatry and Mental healthItalyPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)NeurosurgeryPhase IVbusinessFollow-Up Studies
researchProduct

HOMOZIGOUS DJ-1 MUTATION IN A FAMILY FROM SOUTHERN ITALY WITH AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM-DEMENTIA COMPLEX

2004

researchProduct

Parkin gene analysis in late onset Parkinson's disease families

2004

researchProduct

DJ-1 gene in late-onset recessive Parkinson's Disease

2004

researchProduct

P.0171 The independent and joint effect of the endocannabinoid system and daily cannabis use on the risk of psychosis

2021

PharmacologyPsychiatry and Mental healthcannabiNeurologyPharmacology (medical)Neurology (clinical)endocannabinoid systempsychosiBiological PsychiatryEuropean Neuropsychopharmacology
researchProduct

Parkin gene analysis in late onset autosomal recessive Parkinson's Disease

2004

researchProduct

Genetic counselling in ALS: facts, uncertainties and clinical suggestions

2013

The clinical approach to patients with amyotrophic lateral sclerosis (ALS) has been largely modified by the identification of novel genes, the detection of gene mutations in apparently sporadic patients, and the discovery of the strict genetic and clinical relation between ALS and frontotemporal dementia (FTD). As a consequence, clinicians are increasingly facing the dilemma on how to handle genetic counselling and testing both for ALS patients and their relatives. On the basis of existing literature on genetics of ALS and of other late-onset life-threatening disorders, we propose clinical suggestions to enable neurologists to provide optimal clinical and genetic counselling to patients and…

medicine.medical_specialtyGenotypeGENETICSGenetic counselingGenetic CounselingGene mutationSettore MED/03 - GENETICA MEDICAmedicineHumansGenetic TestingAmyotrophic lateral sclerosisGenetic discriminationPsychiatryGenetic testingmedicine.diagnostic_testbusiness.industryAmyotrophic Lateral Sclerosismedicine.diseasePenetranceALS; GENETICS3. Good healthPsychiatry and Mental healthPhenotypeFrontotemporal DementiaMutationSurgerySettore MED/26 - NeurologiaNeurology (clinical)ALSbusinessMotor neurone diseaseFrontotemporal dementiaJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis.

2013

MATR3 is an RNA- and DNA-binding protein that interacts with TDP-43, a disease protein linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Using exome sequencing, we identified mutations in MATR3 in ALS kindreds. We also observed MATR3 pathology in ALS-affected spinal cords with and without MATR3 mutations. Our data provide more evidence supporting the role of aberrant RNA processing in motor neuron degeneration. © 2014 Nature America, Inc. All rights reserved.

MaleAged Aged; 80 and over Amyotrophic Lateral Sclerosis; genetics/pathology Computational Biology DNA Mutational Analysis DNA-Binding Proteins; metabolism Family Health Female Genetic Predisposition to Disease; genetics Genotype Humans Male Middle Aged Muscle; Skeletal; metabolism/pathology Mutation; genetics Neurologic Examination Nuclear Matrix-Associated Proteins; genetics/metabolism RNA-Binding Proteins; genetics/metabolism Spinal Cord; metabolism/pathologyDNA Mutational Analysisgenetics/metabolismRNA-binding proteinSettore MED/03 - GENETICA MEDICAmedicine.disease_cause0302 clinical medicineNuclear Matrix-Associated ProteinsGenotype80 and overgeneticsAmyotrophic lateral sclerosisExome sequencingGeneticsAged 80 and overNeurologic Examination0303 health sciencesMutationGeneral NeuroscienceRNA-Binding ProteinsSkeletalMiddle AgedDNA-Binding ProteinsMATR3medicine.anatomical_structureSpinal Cordfamilial amyotrophic lateral sclerosisMuscleSettore MED/26 - NeurologiaFemaleFrontotemporal dementiametabolism/pathologyGenotypeArticle03 medical and health sciencesgenetics; familial amyotrophic lateral sclerosismental disordersmedicineHumansGenetic Predisposition to DiseaseMuscle Skeletal030304 developmental biologyAgedFamily Healthbusiness.industryAmyotrophic Lateral Sclerosisgenetics/pathologyRNAComputational BiologySpinal cordmedicine.diseaseMutationgeneticbusinessNeurosciencemetabolism030217 neurology & neurosurgery
researchProduct